rimonabant Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was first-in-class for clinical development.   Wikipedia

Chemistry

  • SMILES: Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1
  • InChIKey: JZCPYUJPEARBJL-UHFFFAOYSA-N
  • Mol. Mass: 463.8
  • ALogP: 5.94
  • ChEMBL Molecule:
    rimonabant  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

acomplia | n-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide hydrochloride | rimonabant | sr-14171 | sr141716 | sr 141716 | sr-141716 | sr141716a | sr 141716a | sr-141716a | zimulti

Organizations (24)

Research & Development (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (1)


 

Obesity

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Albuminuria (Phase 3)

Alcohol Drinking (Phase 2)

Alcoholism ()

Arteriosclerosis (Phase 3)

Atherosclerosis (Phase 4)

Cannabis (Phase 2)

Cardiovascular Diseases (Phase 4)

Carotid Stenosis (Phase 3)

Cigarette Smoking (Phase 3)

Coronary Artery Disease (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Dyslipidemias (Phase 3)

Fatty Liver (Phase 3)

Feeding and Eating Disorders (Phase 3)

Healthy Volunteers (Phase 2)

Hypertension (Phase 2)

Marijuana Abuse (Phase 2)

Metabolic Syndrome (Phase 3)

Obesity (Phase 4)

Pain (Phase 1)

Prader-Willi Syndrome (Phase 3)

Prediabetic State (Phase 3)

Psychotic Disorders (Phase 2)

Schizophrenia (Phase 2)

Smoking (Phase 2)

Smoking Cessation (Phase 3)

Spinal Cord Injuries (Phase 2)

Weight Loss (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 46
  • # of Trial Organizations: 24

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue